Xiaoshuang Niu1, Chaosu Hu, Lin Kong. 1. Department of Radiation Oncology, Shanghai Cancer Center of Fudan University, 270 Dong'an Road, Shanghai, 200032, China.
Abstract
PURPOSE: To evaluate the safety and efficacy of cetuximab plus intensity-modulated radiotherapy (IMRT) with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: From June 2007 to December 2010, 33 patients with stage II (12 %), III (33 %), IVA (33 %), and IVB (21 %) NPC were treated at our hospital. Cetuximab was administered at an initial dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2). All patients completed IMRT, and a total dose of 66-70.4, 66, 60, and 54 Gy were given to the gross tumor volume, positive neck nodes, high-risk clinical target volume, and low-risk clinical target volume, respectively. Most patients (90.9 %) received platinum-based neoadjuvant, concurrent, or adjuvant chemotherapy. The efficacy and safety were evaluated retrospectively. RESULTS: With a median follow-up of 40.0 months, the 3-year progression-free survival (PFS), distant metastasis-free survival, and overall survival were 70.5 % (95 % CI 54.0-87.0 %), 83.6 % (95 % CI 70.3-96.9 %), and 90.9 % (95 % CI 81.1-100.0 %), respectively. Majority (75.8 %) of patients received ≥ 7 cycles of cetuximab (median 7 cycles, range 2-14 cycles). Patients who received ≥ 7 cycles of cetuximab showed a better 3-year PFS than those receiving <7 cycles (79.1 vs. 31.2 %, p = 0.050). During cetuximab + IMRT, stomatitis was the most common acute treatment toxicity, 23 (69.7 %) and 5 (15.2 %) patients with grade 3 and grade 4 stomatitis, respectively. Temporal lobe necrosis was observed in 7 patients. CONCLUSIONS: Cetuximab plus IMRT with or without chemotherapy for locoregionally advanced NPC is effective and tolerated. Further investigations are warranted.
PURPOSE: To evaluate the safety and efficacy of cetuximab plus intensity-modulated radiotherapy (IMRT) with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: From June 2007 to December 2010, 33 patients with stage II (12 %), III (33 %), IVA (33 %), and IVB (21 %) NPC were treated at our hospital. Cetuximab was administered at an initial dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2). All patients completed IMRT, and a total dose of 66-70.4, 66, 60, and 54 Gy were given to the gross tumor volume, positive neck nodes, high-risk clinical target volume, and low-risk clinical target volume, respectively. Most patients (90.9 %) received platinum-based neoadjuvant, concurrent, or adjuvant chemotherapy. The efficacy and safety were evaluated retrospectively. RESULTS: With a median follow-up of 40.0 months, the 3-year progression-free survival (PFS), distant metastasis-free survival, and overall survival were 70.5 % (95 % CI 54.0-87.0 %), 83.6 % (95 % CI 70.3-96.9 %), and 90.9 % (95 % CI 81.1-100.0 %), respectively. Majority (75.8 %) of patients received ≥ 7 cycles of cetuximab (median 7 cycles, range 2-14 cycles). Patients who received ≥ 7 cycles of cetuximab showed a better 3-year PFS than those receiving <7 cycles (79.1 vs. 31.2 %, p = 0.050). During cetuximab + IMRT, stomatitis was the most common acute treatment toxicity, 23 (69.7 %) and 5 (15.2 %) patients with grade 3 and grade 4 stomatitis, respectively. Temporal lobe necrosis was observed in 7 patients. CONCLUSIONS:Cetuximab plus IMRT with or without chemotherapy for locoregionally advanced NPC is effective and tolerated. Further investigations are warranted.
Authors: Athanassios Argiris; Dwight E Heron; Ryan P Smith; Seungwon Kim; Michael K Gibson; Stephen Y Lai; Barton F Branstetter; Donna M Posluszny; Lin Wang; Raja R Seethala; Sanja Dacic; William Gooding; Jennifer R Grandis; Jonas T Johnson; Robert L Ferris Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Søren M Bentzen; Beste M Atasoy; Frances M Daley; Stanley Dische; Paul I Richman; Michele I Saunders; Klaus R Trott; George D Wilson Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: David G Pfister; Yungpo Bernard Su; Dennis H Kraus; Suzanne L Wolden; Eric Lis; Timothy B Aliff; Andrew J Zahalsky; Simone Lake; Michael N Needle; Ashok R Shaha; Jatin P Shah; Michael J Zelefsky Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Anthony T C Chan; Mow-Ming Hsu; Boon C Goh; Edwin P Hui; Tsang-Wu Liu; Michael J Millward; Ruey-Long Hong; Jacqueline Whang-Peng; Brigette B Y Ma; Ka F To; Matthias Mueser; Nadia Amellal; Xiao Lin; Alex Y Chang Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Suzanne L Wolden; William C Chen; David G Pfister; Dennis H Kraus; Sean L Berry; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-02 Impact factor: 7.038
Authors: P M Teo; S F Leung; A T Chan; T W Leung; P H Choi; W H Kwan; W Y Lee; R M Chau; P K Yu; P J Johnson Journal: Int J Radiat Oncol Biol Phys Date: 2000-12-01 Impact factor: 7.038
Authors: Quynh Thu Le; A Dimitrios Colevas; Brian O'Sullivan; Anne W M Lee; Nancy Lee; Brigette Ma; Lillian L Siu; John Waldron; Chwee-Ming Lim; Nadeem Riaz; Jean Lynn; Shakun Malik Journal: J Natl Cancer Inst Date: 2019-07-01 Impact factor: 13.506
Authors: Victor H F Lee; Anthony W I Lo; Chun-Yin Leung; Wai-Hung Shek; Dora L W Kwong; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze; To-Wai Leung Journal: PLoS One Date: 2016-06-24 Impact factor: 3.240